A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in wh...

Full description

Bibliographic Details
Published in:	Терапевтический архив
Main Authors:	Ol'ga Veniaminovna Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva, O V Stakhina
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2010-02-01
Subjects:	chronic myeloid leukemia drug-induced pneumonitis interstitial pneumonia imatinib mesylate
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/30558

Similar Items

Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
by: Zhuan - Bo Luo, et al.
Published: (2017-11-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

Generic Imatinib Mesylate as first-line treatment of chronic myeloid leukemia.
by: Brahim Benzineb, et al.
Published: (2023-04-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
by: Ahmet Emre Eşkazan, et al.
Published: (2013-12-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)

A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line
by: Corrêa Stephany, et al.
Published: (2012-03-01)

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi
by: Anil Babar, et al.
Published: (2024-04-01)

Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
by: Shreya Agrawal, et al.
Published: (2023-01-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases Tratamento da leucemia mielóide crônica com imatinib mesilato no Brasil: estudo de 98 casos
by: Vaneuza A. M. Funke, et al.
Published: (2005-09-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients
by: Maedeh Khosravi, et al.
Published: (2021-05-01)

Determination of imatinib mesylate and erlotinib hydrochloride in mice plasma using ultrahigh performance liquid chromatography method
by: Gülen Melike Demir, et al.
Published: (2018-08-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Imatinib mesylate resistance and mutations: An Indian experience
by: Shweta Srivastava, et al.
Published: (2013-01-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis
by: Megan E. Perkins, et al.
Published: (2022-05-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
by: Caterina Musolino, et al.
Published: (2015-05-01)

A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate
by: E. B. Myakoshina, et al.
Published: (2020-09-01)

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
by: Kritamorn Jitrangsri, et al.
Published: (2023-09-01)

Subclinical Hypothyroidism Following Imatinib Use in Nigerian BCR::ABL1-positive Chronic Myeloid Leukemia Patients: A Prospective Cohort Study
by: Ibrahim Oluwaseun Ahmed, et al.
Published: (2024-09-01)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report
by: Clara Saldarriaga, et al.
Published: (2008-12-01)

Nail lichen planus associated with imatinib mesylate
by: Eden Axler, BS, et al.
Published: (2025-04-01)

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
by: Xiuyan Zhang, et al.
Published: (2023-10-01)